Matthew joined Cyagen as Vice President of Business Development and Strategy bringing extensive experience in driving growth, building strategic partnerships, and leading high-performing teams in the advanced therapies sector.

Matthew holds a PhD in Biochemistry from Imperial College London and was a Group Leader at the Max-Planck Institute for Heart and Lung Research. Matthew's passion lies at the intersection of science and business, enabling innovative life science companies to accelerate growth, attract investment, and deliver transformative therapies to patients.

Ivan is an accomplished scientific leader with extensive experience at the intersection of biomedical research and commercial innovation. He holds a PhD from Monash University's Australian Regenerative Medicine Institute, following a First-Class Honours degree in Medical Bioscience.

With a career spanning Europe and Asia, Ivan has led international teams, developed new business territories, and built partnerships with CRO and pharmaceutical organisations. His combination of scientific expertise and commercial strategy will support Cyagen's continued expansion and success across global markets.

Mario holds an MSc in Biological Sciences and a PhD in Medical Biotechnology. He spent nearly a decade in academic research in the UK investigating transcription-factor networks in B-cell differentiation and their dysregulation in hematologic cancers.

He later served as a scientific lead in preclinical immunology and immunotoxicology, supporting drug-development programmes across small molecules, checkpoint inhibitors, and cell and gene therapies. Transitioning into business development, Mario now applies his combined scientific and commercial expertise to build partnerships, support therapeutic innovation, and drive growth across the UK market.